Maligne Non-Hodgkin-Lymphome: Erscheinungsformen und Behandlung

  • C. R. Meier
Conference paper

Zusammenfassung

Die bösartigen Geschwulstkrankheiten lymphatischer Gewebe (maligne Lymphome) werden in zwei Hauptgruppen eingeteilt, die sich histopathologisch und in ihrem biologischen Verhalten vielfach unterscheiden, nämlich einerseits Morbus Hodgkin (Lymphogranulomatose), und andererseits ein ganzes Spektrum unterschiedlicher Entitäten, für welches sich in neuerer Zeit der Terminus Non-Hodgkin-Lymphome (NHL) eingebürgert hat. Der vorliegende Beitrag befaßt sich hauptsächlich mit den NHL des Erwachsenenalters.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Anderson JL, Bieber CP, Fowles RE, Stinson EB (1978) Idiopathic cardiomyopathy, age, and suppressor cell dysfunction as risk determinants of lymphoma after cardiac transplantation. Lancet 2:1174–1177PubMedGoogle Scholar
  2. 2.
    Anderson T, Bender RA, Fisher RI et al. (1977) Combination chemotherapy in Non-Hodgkin’s Lymphoma: Results of long-term follow-up. Cancer Treat Rep 61:1057–1066PubMedGoogle Scholar
  3. 3.
    Avdani SH, Dinshaw KA, Nair CN et al. (1980) Immune dysfunction in Non-Hodgkin–s lymphoma. Cancer 45:2843–2848Google Scholar
  4. 4.
    Banfe A, Bonadonna G, Riece SB et al. (1972) Malignant lymphomas of Waldeyer’s ring — Natural history and survival after radiotherapy. Br Med J 2:140–143Google Scholar
  5. 5.
    Bennett MH, Farrer-Brown G, Henry K et al. (1974) Classification of Non-Hodgkin’s lymphomas. Lancet 2:405–406Google Scholar
  6. 6.
    Best JJK, Blackledge G, Forbes WS et al. (1978) Computed tomography of abdomen in staging and clinical management of lymphoma. Br Med J 2:1675–1677PubMedGoogle Scholar
  7. 7.
    Bitran JD, Kinzie J, Sweet DL, Variakojis D et al. (1977) Survival of patients with localized histiocytic lymphoma. Cancer 39:342–346PubMedGoogle Scholar
  8. 8.
    Bitran JD, Golomb HM, Ultmann JE et al. (1978) Non-Hodgkin’s lymphoma, poorly differentiated lymphocytic and mixed cell types: Results of sequential staging procedures, response to therapy, and survival of 100 patients. Cancer 42:88–95PubMedGoogle Scholar
  9. 9.
    Bonadonna G, DeLena M, Lattuada A et al. (1975) Combination chemotherapy and radiotherapy in Non-Hodgkin’s lymphomata. Br J Cancer (suppl 2):481–488Google Scholar
  10. 10.
    Brill NE, Baehr G, Rosenthal N (1925) Generalized giant lymph follicle hyperplasia of lymph nodes and spleen. A hitherto undescribed type. JAMA 84:668–671Google Scholar
  11. 11.
    Brittinger G, Schmalhorst U, Bartels H et al. (1981) Principles and present status of a prospective multicenter study on the clinical relevance of the Kiel classification. Blut 43:155–166PubMedGoogle Scholar
  12. 12.
    Broder S, Edelson RL, Lutzner MA et al. (1976) The Sézary syndrome: A malignant proliferation of helper T cells. J Clin Invest 58:1297–1306PubMedGoogle Scholar
  13. 13.
    Brown TC, Peters MV, Bergsagel DE et al. (1975) A retrospective analysis of the clinical results in relation to the Rappaport histological classification. Br J Cancer 31 (suppl 2): 174–186Google Scholar
  14. 14.
    Bunn PA, Schein PS, Banks PM et al. (1976) Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: Leukemia revisited. Blood 47:3–10PubMedGoogle Scholar
  15. 15.
    Bunn PA, Lamberg SI (1979) Report of the committee on cutaneous T-cell lymphoma: Staging classification. Cancer Treat Rep 63:725–728PubMedGoogle Scholar
  16. 16.
    Burgener FA, Hamlin DJ (1981) Intrathoracic histiocytic lymphoma. AJR 136:499–504PubMedGoogle Scholar
  17. 17.
    Bush RS, Gospodarowicz M, Sturgeon J, Alison R (1977) Radiation therapy of localized Non-Hodgkin’s lymphoma. Cancer Treat Rep 61:1129–1136PubMedGoogle Scholar
  18. 18.
    Cabanillas F, Bodey GP, Freireich EJ (1980) Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer 46:2356–2359PubMedGoogle Scholar
  19. 19.
    Cabre-Fiol V, Vilardell F (1978) Progress in the cytologic diagnosis of gastric lymphoma. Cancer 41:1456–1461PubMedGoogle Scholar
  20. 20.
    Canellos GP, DeVita VT, Young RC et al. (1975) Therapy of advanced lymphocytic lymphoma; a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy. Br J Cancer 31 (suppl 2): 474–480Google Scholar
  21. 21.
    Carabell SC, Chaffey JT, Rosenthal DS et al. (1979) Results of total body irradiation in the treatment of advanced Non-Hodgkin’s lymphomas. Cancer 43:994–1000PubMedGoogle Scholar
  22. 22.
    Carbone PP, Kaplan HS, Musshoff K et al. (1971) Report of the committee on Hodgkin’s disease staging. Cancer Res 31:1860–1861PubMedGoogle Scholar
  23. 23.
    Castellino RA, Goffinet DR, Blank N et al. (1974) The role of radiography in the staging of Non-Hodgkin’s lymphoma with laparotomy correlation. Radiology 110:329–338PubMedGoogle Scholar
  24. 24.
    Chabner BA, Johnson RE, Young RC et al. (1976) Sequential nonsurgical and surgical staging of Non-Hodgkin’s lymphoma. Ann Intern Med 85:149–155PubMedGoogle Scholar
  25. 25.
    Coller BS, Chabner BA, Gralnick HR (1979) Frequencies and patterns of bone marrow involvement in the Non-Hodgkin’s lymphomas: Observation on the value of bilateral biopsies. Am J Hematol 3:105–119Google Scholar
  26. 26.
    Connors J, Wise L (1974) Management of gastric lymphomas. American J Surgery 127:102–107Google Scholar
  27. 27.
    Court-Brown WM, Doll R (1965) Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br Med J 2:1327–1332Google Scholar
  28. 28.
    DeVita VT, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC (1975) Advanced diffuse histiocytic lymphoma, a potentially curable disease. Results with combination chemotherapy. Lancet 1:248–250PubMedGoogle Scholar
  29. 29.
    DeVita VT, Hellman S (1982) Hodgkin’s disease and the Non-Hodgkin’s lymphomas. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer — Principles and practice of oncology. Lippincott, PhiladelphiaGoogle Scholar
  30. 30.
    DeVita VT (1979) Human models of human disease: Breast cancer and the lymphomas. Intl J Rad Onc Biol Phys 5:1855–1867Google Scholar
  31. 31.
    Dick F, Bloomfield CD, Brunning CD (1974) Incidence, cytology, and histopathology of Non-Hodgkin’s lymphomas in the bone marrow. Cancer 33:1382–1398PubMedGoogle Scholar
  32. 32.
    Dorfman RF (1974) Classification of Non-Hodgkin’s lymphomas. Lancet 1:1295–1296PubMedGoogle Scholar
  33. 33.
    Dreschfeld J (1892) Clinical lecture on acute Hodgkin’s (or pseudoleucocythemia). Br Med J 1:893–996PubMedGoogle Scholar
  34. 34.
    Epstein EH, Levine DL, Croft JD et al. (1972) Mycosis fungoides: Survival, prognostic features, response to therapy, and autopsy findings. Medicine (Baltimore) 51:61–72Google Scholar
  35. 35.
    Ewing J (1928) Neoplastic diseases (ed 3). Philadelphia, Saunders, p 414Google Scholar
  36. 36.
    Fisher RI, DeVita VT, Hubbard SM et al. (1980) ProMACE-MOPP combination chemotherapy: Treatment of diffuse lymphomas (Abstract) Proc Am Soc Clin Oncol 21:468Google Scholar
  37. 37.
    Fisher RI, Hubbard SM, DeVita VT, Berard CW et al. (1981) Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 58:45–51PubMedGoogle Scholar
  38. 38.
    Fisher RI, DeVita VT, Johnson BL et al. (1977) Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 63:177–182PubMedGoogle Scholar
  39. 39.
    Fox H (1926) Remarks on microscopical preparations made from some of the original tissue described by Thomas Hodgkin 1832. Ann Med History 8:370–374Google Scholar
  40. 40.
    Frizzera G, Hanto DW, Gajl-Peczalska KJ et al. (1981) Polymorphic diffuse B cell hyperplasia and lymphomas in renal transplant recipiants. Cancer Res 41:4262–4279PubMedGoogle Scholar
  41. 41.
    Fu SM, Winchester RJ, Feizi T, Walzer PD, Kunkel HJ (1974) Idiopathic specificity of surface immunoglobulin and the maturation of leukemic bone marrow derived lymphocytes. Proc Natl Acad Sci USA 71:4487–4490PubMedGoogle Scholar
  42. 42.
    Garvin AJ, Simon R, Young RC, DeVita VT, Berard CW (1980) The Rappaport classification of Non-Hodgkin’s lymphomas: A closer look using other proposed classifications. Semin Oncology 7:234–243Google Scholar
  43. 43.
    Gatti RA, Good RA (1971) Occurrence of malignancy in immunodeficiency diseases. Cancer 28:89–98PubMedGoogle Scholar
  44. 44.
    Gerard-Marchant R, Hamlin I, Lennert K, Rilke F, Stansfeld AG, van Unnik JAM (1974) Classification of Non-Hodgkin’s lymphomas. Lancet 2:406–408Google Scholar
  45. 45.
    Glatstein E, Fuks 7, Goffinet DR et al. (1976) Non-Hodgkin’s lymphoma of stage III extent: Is total lymphoid irradiation appropriate treatment? Cancer 37:2806–2812PubMedGoogle Scholar
  46. 46.
    Golomb H (1958) „Hairy“ cell leukemia: An unusual lymphoproliferative disease. Cancer 42:946–956Google Scholar
  47. 47.
    Greene MH (1981) Clinical and environmental predisposing factors. In: A multidiscipli-nary approach to Non-Hodgkin’s lymphomas (NIH conference), Berard CW (moderator). Ann Intern Med 94:218–235PubMedGoogle Scholar
  48. 48.
    Greene MH, Miller RW (1978) Familiar Non-Hodgkin lymphoma: Histologic diversity and relation to other cancers. Am J Med Gen 1:437–443Google Scholar
  49. 49.
    Greene MH (1981) The epidemiology of Non-Hodgkin’s lymphoma and Mycosis fungoides. In: Schottenfeld D, Fraumeni JF (eds) The epidemiology and prevention of cancerGoogle Scholar
  50. 50.
    Greene MH, Dalager NA, Lamberg SI et al. (1979) Mycosis fungoides: Epidemiological observations. Cancer Treat Rep 63:597–606PubMedGoogle Scholar
  51. 51.
    Grozea PN, Jones SE, McKelvey EM et al. (1979) Combination Chemotherapy for mycosis fungoides. A Southwest Oncology Group Study. Cancer Treat Rep 63:647–653PubMedGoogle Scholar
  52. 52.
    Gutterman JU, Blumenschein GR, Alexanian R et al. (1980) Leukocyte interferon-in-duced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93:399–406PubMedGoogle Scholar
  53. 53.
    Hande KR, Fisher RI, DeVita VT et al. (1978) Diffuse histiocytic lymphoma involving the gastrointestinal tract. Cancer 41:1984–1989PubMedGoogle Scholar
  54. 54.
    Hanto DW, Sakamoto K, Purtilo DT et al. (1981) The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders: Clinical, pathologic, and virologic correlation. Surgery 90:204–213PubMedGoogle Scholar
  55. 55.
    Hanto DW, Frizzera G, Gajl-Peczalska KJ et al. (1982) Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. New Engl J Medicine 306:913–918Google Scholar
  56. 56.
    Harsock RJ (1968) Postvaccinial lymphadenitis: Hyperplasia of lymphoid tissue that simulates malignant lymphoma. Cancer 21:632Google Scholar
  57. 57.
    Hattori T, Uchiyama T, Toibana T et al. (1981) Surface phenotype of Japanese T-cell leukemia cells characterized by monoclonal antibodies. Blood 58:645–647PubMedGoogle Scholar
  58. 58.
    Herman TS, Jones SE (1977) Systematic restaging in the management of Non-Hodgkin’s lymphoma. Cancer Treat Rep 61:1009–1015PubMedGoogle Scholar
  59. 59.
    Hoppe RT, Cox RS, Fuks ZY et al. (1979) Electron beam therapy in the treatment of mycosis fimgoides — the Stanford experience. Cancer Treat Rep 63:691–700PubMedGoogle Scholar
  60. 60.
    Huberman M, Bunn PA, Matthews MJ et al. (1979) Extracutaneous involvement in patients with cutaneous T-cell lymphomas (Mycosis fungoides and Sezary syndrome). Proc AACR and ASCO 20:410Google Scholar
  61. 61.
    Jaffe ES, Shevach EM, Frank MM et al. (1974) Nodular lymphoma: Evidence for origin from follicular B Lymphocytes. New Engl J Medicine 290:813–819Google Scholar
  62. 62.
    Jaffe ES, Braylan RC, Frank MM et al. (1976) Heterogeneity of immunologic markers and surface morphology in childhood lymphoblastic lymphoma. Blood 48:213–222PubMedGoogle Scholar
  63. 63.
    Johnson RE, DeVita VT, Kun LE et al. (1975) Patterns of involvement with malignant lymphoma and implications for treatment decision making. Brit J Cancer 31 (Suppl 12):237–241Google Scholar
  64. 64.
    Jones SE, Fuks Z, Kaplan HS et al. (1973) Non-Hodgkin’s lymphomas. Results of radiotherapy. Cancer 32:682–691PubMedGoogle Scholar
  65. 65.
    Jones SE, Rosenberg SA, Kaplan HS et al. (1972) Non-Hodgkin’s lymphomas. II Single agent chemotherapy. Cancer 30:31PubMedGoogle Scholar
  66. 66.
    Jones SE, Rosenberg SA, Kaplan HS (1972) Non-Hodgkin’s lymphoma. I. Bone marrow involvement. Cancer 29:954–960PubMedGoogle Scholar
  67. 67.
    Jones SE, Fuks Z, Bull M et al. (1973) Non-Hodgkin’s lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer 31:806–823PubMedGoogle Scholar
  68. 68.
    Jones R, Hubbard SM, Osborne C et al. (1978) Histologic conversions in Non-Hodgkin’s lymphoma: Evolution of nodular lymphomas to diffuse lymphomas. Clinic Research 26:437Google Scholar
  69. 69.
    Jones SE, Butler JJ, Byrne GE et al. (1977) Histopathologic review of lymphoma cases from the Southwest Oncology Group. Cancer 39:1071–1076PubMedGoogle Scholar
  70. 70.
    Jones SE (1973) Autoimmune disorders and malignant lymphoma. Cancer 31:1092–1098PubMedGoogle Scholar
  71. 71.
    Kaplan HS (1974) Leukemia and lymphoma in experimental and domestic animals. Sem Hematol 7:94–163Google Scholar
  72. 72.
    Kay HEM (1974) Classification of Non-Hodgkin’s lymphomas. Lancet 2:586PubMedGoogle Scholar
  73. 73.
    Kennedy BJ, Bloomfield CD, Kiang DT et al. (1978) Combination vs. successive single agent chemotherapy in lymphocytic lymphoma. Cancer 41:23–28PubMedGoogle Scholar
  74. 74.
    Kinlen LJ, Schiel AGR, Peto J, Doll RA (1979) A collaborative study of cancer in patients who have received immunosuppressive therapy. Br Med J 2:1461–1466PubMedGoogle Scholar
  75. 75.
    Klein G (1979) Lymphoma development in mice and humans: Diversity of initiation as followed by convergent cytogenetic evolution. Proc Natl Acad Sci USA 76:2442–2446PubMedGoogle Scholar
  76. 76.
    Ko HS, Pruzanski W (1976) M components associated with lymphoma: A review of 62 cases. Amer J Med Sci 272:175–183PubMedGoogle Scholar
  77. 77.
    Koziner B, Little C, Passe S et al. (1982) Treatment of advanced diffuse histiocyclic lymphoma: An analysis of prognostic variables. Cancer 49:1571–1579PubMedGoogle Scholar
  78. 78.
    Laurence J, Coleman M, Allen SL et al. (1982) Combination chemotherapy of advanced diffuse histiocytic lymphoma with a six-drug COP-BLAM regimen. Ann Intern Med 97:190–195PubMedGoogle Scholar
  79. 79.
    Leech JH, Glick AD, Waldron JA et al. (1975) Malignant lymphomas of follicular center cell origin in man. I. Immunologic studies. J Natl Cancer Inst 54:11–22PubMedGoogle Scholar
  80. 80.
    Lennert K (1977) Klassifikation der Non-Hodgkin Lymphome im Kindesalter. Klin Paediat 189:7–13Google Scholar
  81. 81.
    Lester JN, Fuller LM, Conrad FG et al. (1982) The roles of staging laparotomy, chemotherapy, and radiotherapy in the management of localized diffuse large cell lymphoma: A study of 75 patients. Cancer 49:1746–1753PubMedGoogle Scholar
  82. 82.
    Lister TA, Cullen MH, Beard MEJ et al. (1978) Comparison of combined and single agent chemotherapy in Non-Hodgkin’s Lymphoma of favourable histological type. British Medical J 1:533–537Google Scholar
  83. 83.
    Luddy RE, Sutherland JC, Levy BE, Schwartz AD (1982) Cat-scratch disease simulating malignant lymphoma. Cancer 50:584–586PubMedGoogle Scholar
  84. 84.
    Lukes RJ, Collins RD (1977) Lukes-Collins classification and its significance. Cancer Treat Rep 61:971–979PubMedGoogle Scholar
  85. 85.
    Lukes RJ, Collins RD (1974) Immunologic characterization of human malignant lymphomas. Cancer 34:1488–1503PubMedGoogle Scholar
  86. 86.
    Mann RB, Jaffe ES, Berard CW (1979) Malignant lymphomas — A conceptual understanding of morphologic diversity. Am J Pathol 94:103–192Google Scholar
  87. 87.
    Minna JD, Roenigk HH jr, Glatstein E: Report of the committee on therapy for mycosis fungoides and Sézary syndrome. Cancer Treat Rep 63:729–736Google Scholar
  88. 88.
    McKelvey EM, Gottlieb JA, Wilson HE et al. (1976) Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484–1493PubMedGoogle Scholar
  89. 89.
    McKenna RW, Bloomfield CD, Brunning RD (1975) Nodular lymphoma: Bone marrow and blood manifestations. Cancer 36:428–440PubMedGoogle Scholar
  90. 90.
    Miller TP, Jones SE (1979) Chemotherapy of localized histiocytic lymphoma. Lancet 1:358–360PubMedGoogle Scholar
  91. 91.
    Miller JB, Variakojis D, Bitran JD et al. (1981) Diffuse histiocytic lymphoma with sclerosis: A clinicopathologic entity frequently causing superior vena cava obstruction. Cancer 47:748–756PubMedGoogle Scholar
  92. 92.
    Miller R, Maloney DJ, Warnke R, Levy R (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. New Engl J Medicine 306:517–522Google Scholar
  93. 93.
    Moore DF, Migliore FH, Shullenberger CC et al. (1970) Monoclonal macroglobulinemia in malignant lymphoma. Ann Intern Med 72:43PubMedGoogle Scholar
  94. 94.
    Moran EM, Ultmann JE, Ferguson DJ et al. (1975) Staging laparotomy in Non-Hodg-kin’s lymphoma. Br J Cancer 31 (Suppl 2): 228–236Google Scholar
  95. 95.
    Murphy SB (1980) Classification, staging and end results of treatment of childhood Non-Hodgkin’s lymphomas: Dissimilarities from lymphomas in adults. Sem Oncology 7:332–339Google Scholar
  96. 96.
    Nathwani BN, Dixon DO, Jones SE et al. (1982) The clinical significance of the morphological subdivision of diffuse histiocytic lymphoma: A study of 162 patients treated by the Southwest Oncology Group. Blood 60:1068–1074PubMedGoogle Scholar
  97. 97.
    Nathwani BN, Kim H, Rappaport H (1976) Malignant lymphoma, lymphoblastic. Cancer 38:964–983PubMedGoogle Scholar
  98. 98.
    Nissen NJ, Pajak T, Glidewell O et al. (1977) Overview of four clinical studies of chemotherapy for stage III and IV Non-Hodgkin’s lymphomas by the Cancer and Leukemia Group B. Cancer Treat Rep 61:1097–1107PubMedGoogle Scholar
  99. 99.
    Patterson SD, Larson EB, Corey L (1980) Atypical generalized zoster with lymphadenitis mimicking lymphoma. New Engl J Medicine 302:848Google Scholar
  100. 100.
    Portlock CS (1980) Management of the indolent Non-Hodgkin’s Lymphomas. Sem Oncology 7:292’301Google Scholar
  101. 101.
    Portlock CS, Rosenberg SA (1977) Chemotherapy of the Non-Hodgkin’s Lymphomas: The Stanford experience. Cancer Treat Rep 61:1049’1055PubMedGoogle Scholar
  102. 102.
    Portlock CS, Rosenberg SA (1979) No initial therapy for stage III and IV Non-Hodgkin’s lymphomas of favorable histologic types. Ann Intern Med 90:10–13PubMedGoogle Scholar
  103. 103.
    Rappaport H (1966) Tumors of the hematopoietic system. In: Atlas of tumor pathology Sec. 3, Fascicle 8. Washington, D.C., Armed Forces Institute of Pathology, p 97–161Google Scholar
  104. 104.
    Rappaport H, Winter WJ, Hicks EB (1956) Follicular lymphoma. A re-evaluation of its position in the scheme of malignant lymphoma based on a survey of 253 cases. Cancer 9:792–821PubMedGoogle Scholar
  105. 105.
    Raso V, Ritz J, Basala M, Schlossman S (1982) Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. Cancer Res 42:457–464PubMedGoogle Scholar
  106. 106.
    Reimer RR, Chabner BA, Young RC et al. (1977) Lymphoma presenting in bone. Results of histopathology, staging, and therapy. Ann Intern Med 87:50–55PubMedGoogle Scholar
  107. 107.
    Rosenberg SA, Diamond HD, Jaslowitz B et al. (1961) Lymphosarcoma: A review of 1269 cases. Medicine 40:31PubMedGoogle Scholar
  108. 108.
    Rosenberg SA, Kaplan HS (1968) The results of radical radiotherapy in Hodgkin’s disease and other lymphomas. In: Sarafonitis CJD (ed): Proceedings of the international conference on leukemia-lymphoma. Philadelphia, Lee and Febiger, pp 403–408Google Scholar
  109. 109.
    Rosenberg SA et al. (1982) National Cancer Institute sponsored study of classifications of Non-Hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112–2135Google Scholar
  110. 110.
    Rowley JD, Fukuhara S (1980) Chromosome studies in Non-Hodgkin’s lymphomas. Sem Oncology 7:255–266Google Scholar
  111. 111.
    Sage HH (1958) Palpable cervical lymph nodes. JAMA 168:496–498Google Scholar
  112. 112.
    Saltzstein SL, Eckerman LD (1959) Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas. Cancer 12:164PubMedGoogle Scholar
  113. 113.
    Salvador AH, Harrison EJ, Kyle RA (1971) Lymphadenopathy due to infectious mononucleosis: Its confusion with malignant lymphoma. Cancer 27:1029PubMedGoogle Scholar
  114. 114.
    Schaner EJ, Head GL, Doppman JL et al. (1977) Computer tomography in the diagnosis, staging, and management of abdominal lymphoma. J Computer-Assisted Tomography 1:176–180Google Scholar
  115. 115.
    Schein PS, DeVita VT, Hubbard S et al. (1976) Bleomycm, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 85:417–422PubMedGoogle Scholar
  116. 116.
    Schmalhorst U, Bartels H, Boll I et al. (1981) Clinical and prognostic heterogeneity of Non-Hodgkin Lymphomas of high grade malignancy. Blut 43:201–211PubMedGoogle Scholar
  117. 117.
    Sen L, Borella L (1975) Clinical importance of lymphoblasts with T markers m childhood acute leukemia. New Engl J Medicine 292:828–832Google Scholar
  118. 118.
    Skarin AT, Rosenthal DS, Maloney WC, Frei E (1977) Combination Chemotherapy of advanced Non-Hodgkin lymphoma with Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone (BACOP). Blood 49:759–770PubMedGoogle Scholar
  119. 119.
    Skarin AT, Canellos G, Rosenthal D et al. (1980) Therapy of diffuse histiocytic and undifferentiated lymphoma with high dose Methotrexate and citrovorum factor rescue (MTX/CF), Bleomycin (B), Adriamycin (A), Cyclophosphamide (C), Oncovin (O), and Decadron (D)(M-BACOD)(Abstract) Proc ASCO 21:463Google Scholar
  120. 120.
    Stukonis MK (1978) Cancer incidence cumulative rates. Lyon, France: IARC World Health Organisation (IARC internal technical report 78:002)Google Scholar
  121. 121.
    Sweet DL, Golomb HM, Ultmann JE et al. (1980) Cyclophosphamide, Vincristine, Methotrexate with Leukovorin rescue, and Cytarabin (COMLA) combmation sequential chemotherapy for diffuse histiocytic lymphoma. Ann Intern Med 92:785–790PubMedGoogle Scholar
  122. 122.
    Sweet DL, Collins RD, Stein RS, Ultmann JE (1982) Prognostic significance of the Lukes and Collins classification in patients treated with COMLA. Cancer Treat Rep 66:1107–1111PubMedGoogle Scholar
  123. 123.
    Sweet DL, Kinzie J, Gaeke ME et al. (1981) Survival of patients with localized diffuse histiocytic lymphoma. Blood 58:1218–1223PubMedGoogle Scholar
  124. 124.
    Symmers D (1927) Follicular lymphadenopathy with splenomegaly. Arch Pathol Lab Med 3:816–820Google Scholar
  125. 125.
    Ultmann JE (1982) Cure of histiocytic lymphoma. Ann Intern Med 97:274–275PubMedGoogle Scholar
  126. 126.
    Vonderheid EC, Van Scott EJ, Johnson WC et al. (1977) Topical chemotherapy and immunotherapy of mycosis fungoides: Intermediate-term results. Arch Dermatol 113:454–462PubMedGoogle Scholar
  127. 127.
    Weinstein HJ, Link MP (1979) Non-Hodgkin’s lymphoma in childhood. Clin Hematology 8:699–713Google Scholar
  128. 128.
    Weinstein HJ, Vance ZB, Jaffe N et al. (1979) Improved prognosis for patients with mediast inal lymphoblastic lymphoma. Blood 53:687–693PubMedGoogle Scholar
  129. 129.
    Wilks S (1865) Cases of enlargement of the lymphatic glands and spleen (or, Hodgkin’s disease), with remarks, G. Guy’s Hospital Rep (Series 3) 11:56–67Google Scholar
  130. 130.
    Wong KK, Sweet DL, Variakojis D (1982) The treatment of lymphoblastic lymphoma with antithymocyte globulin. Cancer 50:57–61PubMedGoogle Scholar
  131. 131.
    Young RC, Howser DM, Anderson T et al. (1979) Central nervous system complications of Non-Hodgkin’s lymphoma. The potential role for prophylactic therapy. Amer J Med 66:435–443PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • C. R. Meier

There are no affiliations available

Personalised recommendations